Investors in Biohaven Ltd. Should Contact Levi & Korsinsky Before September 12, 2025 to Discuss Your Rights – BHVN

Core Viewpoint - A class action securities lawsuit has been filed against Biohaven Ltd. due to alleged securities fraud affecting investors between March 24, 2023, and May 14, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Biohaven Ltd. made false statements regarding the regulatory prospects of its product candidate, troriluzole, for treating SCA, and the sufficiency of data submitted for its regulatory approval [2]. - It is alleged that the efficacy and clinical prospects of another product, BHV-7000, for treating bipolar disorder were also overstated [2]. - The lawsuit suggests that the revelations of these misstatements would likely have a significant negative impact on Biohaven's business and financial condition [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 12, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].